- Home
- AMPY vs NYXH Comparison
AMPY vs NYXH Comparison
Compare AMPY & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMPY | NYXH |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 188.1M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMPY | NYXH |
|---|---|---|
| Price | $4.61 | $4.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $11.00 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 606.1K | 35.2K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $275,827,100.00 | $6,616,215.00 |
| Revenue This Year | N/A | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $2.27 | $4.35 |
| 52 Week High | $6.62 | $11.87 |
Technical Indicators
Market Signals| Indicator | AMPY | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 53.99 |
| Support Level | $4.36 | $4.45 |
| Resistance Level | $4.66 | $5.03 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 40.83 | 81.90 |
Price Performance
Historical ComparisonAbout AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.